• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.

作者信息

Cheadle Eleanor J, Sidon Lauren, Dovedi Simon J, Melis Monique H M, Alduaij Waleed, Illidge Tim M, Honeychurch Jamie

出版信息

Br J Haematol. 2013 Sep;162(6):842-5. doi: 10.1111/bjh.12427. Epub 2013 Jun 18.

DOI:10.1111/bjh.12427
PMID:23772929
Abstract
摘要

相似文献

1
The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.与I型利妥昔单抗相比，II型抗CD20单克隆抗体诱导免疫原性细胞死亡存在机制上的差异。
Br J Haematol. 2013 Sep;162(6):842-5. doi: 10.1111/bjh.12427. Epub 2013 Jun 18.
2
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.联合抗 CD74（美罗华）和抗 CD20（利妥昔单抗）单克隆抗体治疗在套细胞淋巴瘤中有体外和体内活性。
Blood. 2011 Apr 28;117(17):4530-41. doi: 10.1182/blood-2010-08-303354. Epub 2011 Jan 12.
3
Enhancement of anti-lymphoma immuno-effects mediated by dendritic cells pulsed with heat-stressed and rituximab-coated CD20+ lymphoma cells.
Int J Hematol. 2008 Jun;87(5):459-466. doi: 10.1007/s12185-008-0072-9. Epub 2008 Apr 15.
4
Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.CD20的表面水平决定了抗CD20抗体在体外介导的细胞死亡。
PLoS One. 2014 Nov 3;9(11):e111113. doi: 10.1371/journal.pone.0111113. eCollection 2014.
5
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.新型 II 型抗 CD20 单克隆抗体（GA101）在 B 细胞恶性肿瘤中引发同型黏附及依赖肌动蛋白、溶酶体介导线粒体死亡。
Blood. 2011 Apr 28;117(17):4519-29. doi: 10.1182/blood-2010-07-296913. Epub 2011 Mar 4.
6
γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.GA101，一种 II 型糖基化工程抗 CD20 单克隆抗体，可显著增强 γδ T 细胞对原发性滤泡性淋巴瘤细胞的杀伤作用。
Haematologica. 2011 Mar;96(3):400-7. doi: 10.3324/haematol.2010.029520. Epub 2010 Nov 25.
7
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.Fcγ 受体介导的 trogocytosis 影响基于单抗的治疗：历史先例和最新进展。
Blood. 2015 Jan 29;125(5):762-6. doi: 10.1182/blood-2014-10-569244. Epub 2014 Dec 10.
8
Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.细胞表面CD20与CD40分子的物理缔合增强利妥昔单抗诱导的细胞死亡。
Int Immunol. 2014 Aug;26(8):451-65. doi: 10.1093/intimm/dxu046. Epub 2014 May 15.
9
The future of anti-CD20 monoclonal antibodies: are we making progress?抗 CD20 单克隆抗体的未来：我们是否在取得进展？
Blood. 2011 Mar 17;117(11):2993-3001. doi: 10.1182/blood-2010-07-298356. Epub 2011 Jan 5.
10
Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.新型人源化抗 CD20 抗体 BM-ca 结合独特表位，比其他抗体具有更强的细胞活性。
Cancer Med. 2013 Apr;2(2):130-43. doi: 10.1002/cam4.60. Epub 2013 Feb 20.

引用本文的文献

1
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.在一项早期滤泡性淋巴瘤全身治疗的随机试验中，辅助性利妥昔单抗和肿瘤内CD8表达升高与放疗后疾病的持续控制相关。
EBioMedicine. 2024 Dec;110:105468. doi: 10.1016/j.ebiom.2024.105468. Epub 2024 Dec 3.
2
Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system.诱导肿瘤发生免疫原性细胞死亡的免疫疗法：固有免疫系统的见解。
Front Immunol. 2023 Nov 23;14:1294434. doi: 10.3389/fimmu.2023.1294434. eCollection 2023.
3
Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861.
奥滨尤妥珠单抗-地辛汀偶联物联合内体逃逸增强剂 SO1861 改善 B 细胞非霍奇金淋巴瘤的治疗。
Toxins (Basel). 2022 Jul 13;14(7):478. doi: 10.3390/toxins14070478.
4
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?治疗性抗体：我们从靶向CD20中学到了什么，又将何去何从？
Front Immunol. 2017 Oct 4;8:1245. doi: 10.3389/fimmu.2017.01245. eCollection 2017.
5
Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?消耗性治疗性单克隆抗体对宿主适应性免疫的影响：是福还是祸？
Front Immunol. 2017 Aug 14;8:950. doi: 10.3389/fimmu.2017.00950. eCollection 2017.
6
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.新型II型抗CD20单克隆抗体奥滨尤妥珠单抗（GA101）治疗B细胞恶性肿瘤患者的综述
Adv Ther. 2017 Feb;34(2):324-356. doi: 10.1007/s12325-016-0451-1. Epub 2016 Dec 21.
7
A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.一种Toll样受体7（TLR7）激动剂通过自然杀伤（NK）细胞和CD4 T细胞增强了奥滨尤妥珠单抗在小鼠淋巴瘤模型中的抗肿瘤疗效。
Leukemia. 2017 Jul;31(7):1611-1621. doi: 10.1038/leu.2016.352. Epub 2017 Nov 28.
8
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.抗癌治疗期间免疫原性与耐受性吞噬作用：机制与临床转化
Cell Death Differ. 2016 Jun;23(6):938-51. doi: 10.1038/cdd.2016.5. Epub 2016 Feb 19.
9
Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.利妥昔单抗诱导的HMGB1释放与人类弥漫性大B细胞淋巴瘤中STAT3活性的抑制有关。
Oncotarget. 2015 Sep 29;6(29):27816-31. doi: 10.18632/oncotarget.4816.